Allergan Inc. said Tuesday that it signed a deal with Pharmacopeia Drug Discovery Inc., a Princeton, N.J. company, to research drug compounds to treat age-related loss of vision.
The two companies are looking to treat macular degeneration, a major cause of vision loss in people 55 and older.
The deal included an undisclosed cash payment from Irvine-based Allergan to Pharmacopeia and could bring preclinical and clinical payments, plus milestone payments and royalties on ophthalmology drugs developed by Allergan.
The drugs will target angiogenesis, or blood vessel growth, in the eye,vessel growth in the eye is associated with the “wet” form of age-related macular degeneration.
